Ed Wijaranakula
Recession Fears Create S&P 500 Buying Opportunities
Gilead Might Want To Consider Selling Its HCV Drug Business To China
Intel And Taiwan Semi Face New Threats From Soaring Silicon Wafer Prices
Buy Celgene And Regeneron On The Dips As Insiders Are Buying
Buy Biotech ETF IBB And Trim Semiconductor Stocks
The Rising 2-Year U.S. Treasury Note Yield And A Weaker Dollar Will Push The S&P 500 Index Towards 3,000
Sell Crude Oil Ahead Of The November OPEC Meeting
Celgene And Biogen Earnings Could Make Or Break The Biotech Sector
Sell U.S. Dollar And Stay Long Gold As Further Fed Rate Hikes Are In Doubt
Gilead And Merck Should Take Drastic Action On Acquisitions As Hepatitis C Drug Market Is Cracking
Gilead's M&A Growth Strategies Becoming Increasingly Limited
Intel: Data Center Faces Growth Challenges
Crude Oil Prices, Oversupply And Currency Risks
Reasons A Regeneron Pharmaceuticals Takeover Is Unlikely
Japanese Yen And Gold Poised For A Rebound As U.S. Dollar Rally May Begin To Fizzle
IBB Biotech ETF: Large-Cap Earnings Could Be Upside Catalyst
Sanofi-Biogen Merger Could Deliver Potential Synergies
Japanese Yen And Gold May Rebound As Strong U.S. Dollar Is Unsustainable
IBB And XBI Biotech ETFs Could Rise As Energy And Financials Sectors Poised For Corrections
U.S. Dollar Rally Could Fizzle As Fed Rate Hike Euphoria Wanes
Here's Why A Biogen And Merck & Co. Merger Remains Unlikely
Intel Data Center Threats Grow As U.S. Economy Stagnant
Gold And Japanese Yen Should Rebound As December Fed Rate Hike May Be Unrealistic
Pfizer's Growth Strategies May Need More Than Just Small Acquisitions
Japanese Yen And Gold Are About To Break Out As The Yield Curve Flattens
Biotech ETF IBB Could Get A Boost From A Potential Gilead Merger Or Acquisitions
How Long Can The U.S. Dollar Index Stay Buoyant Amid Slower Trend Growth Of The U.S. Economy?
Semiconductor ETF Facing Major Headwinds As U.S. Recession Looms
Biotech ETFs IBB And XBI Signal Trend Reversals
Biotech ETF IBB Short Squeeze May Be Ahead
U.S. Dollar Set For A Crash If June Nonfarm Payrolls Disappoints
Eli Lilly Launches Lantus Biosimilar To Boost Sales, But Not Without Risks